ライフサイエンスコーパス: AIDS

1 AIDS Clinical Trial Group 5199 compared neurological and

2 AIDS Clinical Trials Group A5312 is a Phase 2A, open-lab

3 AIDS Clinical Trials Group study A5308 found reduced T-c

4 AIDS is a pandemic disease caused by HIV that affects 37

5 AIDS-associated Kaposi sarcoma attending 11 AIDS Clinical Trials Group sites in Brazil, Kenya, Malaw

6 Among 10156 participants, there were 124 AIDS, 247 SNA, 117 cancers, 103 CVD, and 120 deaths.

7 during 2003-2013 to 31 clinical trials at 99 AIDS Clinical Trials Group network research sites in the

8 International Maternal Pediatric Adolescent AIDS Clinical Trials Network, National Institute of Alle

9 ipants collected longitudinally from 5 Adult AIDS Clinical Trials Group studies incorporating ATI wer

10 ART, supporting its use in treating advanced AIDS-associated Kaposi sarcoma in resource-limited setti

11 Half of persons with advanced AIDS and cryptococcal meningitis had detectable CMV vire

12 mtDNA CN was measured in the ALIVE (AIDS Linked to the Intravenous Experience) cohort of per

13 2014, who contributed to the North American AIDS Cohort Collaboration on Research and Design and who

14 cohorts participating in the North American AIDS Cohort Collaboration on Research and Design.

15 cohorts participating in the North American AIDS Cohort Collaboration on Research and Design.

16 from clinical cohorts in the North American AIDS Cohort Collaboration who initiated their first ART

17 rd Ratio (mHR): 2.2, 95% CI: 1.3-3.6) and an AIDS defining event (mHR: 1.8, 95% CI: 1.1-3.0) were ass

18 etiologic agent of Kaposi's sarcoma (KS), an AIDS-defining cancer in HIV-1-infected individuals or im

19 causative agent of Kaposi's sarcoma (KS), an AIDS-defining cancer with abnormal angiogenesis.

20 l SIV host, African green monkey (AGM) to an AIDS susceptible species, rhesus macaque (RM).

21 As an attractive target for cancer and AIDS treatment, DDX3X and its orthologs are extensively

22 flammatory disease, infertility, cancer, and AIDS.

23 D) demographic and health surveys (DHSs) and AIDS indicator surveys (AISs) (collected between 2008-20

24 iological and clinical data from the HIV and AIDS Reporting System, were used for transmission cluste

25 California HIV and AIDS Research Program and National Institutes of Health-

26 hat may result in the acquisition of HIV and AIDS-related infections.

27 g K Holmes Endowed Professorship in STDs and AIDS.

28 lecules and inflammatory mediators in TB and AIDS, very little attention has been given to their ther

29 search into clinical applications for TB and AIDS.

30 moted MDSC research in tuberculosis (TB) and AIDS.

31 tial enzyme, targeting half of approved anti-AIDS drugs.

32 r enrollment into a trial of third-line ART (AIDS Clinical Trials Group protocol 5288).

33 With antiretroviral therapy (ART), AIDS-defining cancer incidence has declined and non-AIDS

34 are responsible for severe diseases such as AIDS, viral hepatitis, and flu.

35 uals with severe immunodeficiencies, such as AIDS.

36 of simian immunodeficiency virus (SIV) avoid AIDS despite lifelong infection.

37 r Qualified Health Plans (QHPs) purchased by AIDS Drug Assistance Programs (ADAPs) are associated wit

38 r Qualified Health Plans (QHPs) purchased by AIDS Drug Assistance Programs (ADAPs) are associated wit

39 , the secondary lymphoid tissues targeted by AIDS viruses.

40 s and serves as a tool to evaluate candidate AIDS vaccines.

41 he blood of infected animals) that can cause AIDS in this new host.

42 llenge.IMPORTANCE HIV, the virus that causes AIDS, is responsible for millions of infections and deat

43 00 copies per mL), and history of a clinical AIDS diagnosis.

44 Nevertheless, the impact of non-CNS AIDS defining illness (ADI) on brain structure has been

45 invasive vascular tumor and the most common AIDS-associated cancer.

46 roviral therapy, they became the most common AIDS-related cancer in high-income countries.

47 c factors, baseline HIV RNA/CD4 cell counts, AIDS defining events and the type of InSTI.In 646 patien

48 Institutes of Health, and the Thai Red Cross AIDS Research Centre.

49 od, 61 822 patients were followed in the Dat'AIDS cohort; 2027 (10.0%) had PHI and 7314 (36.1%) had P

50 y of MM in PLWH aged >=70 years from the Dat'AIDS French multicenter cohort.

51 ing also minimized total and time-discounted AIDS deaths over 25 years.

52 18, shelters, drug treatment centers (DTCs), AIDS organizations, and Federally Qualified Health Cente

53 Treatment for early AIDS-related KS in previously untreated patients should

54 the small intestine, a site of intense early AIDS virus replication and pathology in rhesus macaques.

55 ANCE It is likely necessary for an effective AIDS vaccine to elicit CD8(+) T cells with the ability t

56 stic development partners is required to end AIDS by 2030.

57 ieve the UNAIDS Fast Track commitment to end AIDS by 2030.

58 cidence rate in the interferon era (European AIDS Treatment Network, NEAT).

59 rnational epidemiology Databases to Evaluate AIDS (IeDEA) consortium: Burundi (N = 11,176), Kenya (N

60 The incidence of clinical events (AIDS, non-AIDS cancer, cardiovascular disease, end-stage

61 mals with SIV infection that were exhibiting AIDS.

62 boratory; University of Rochester Center for AIDS Research and University of Rochester HIV/AIDS Clini

63 the University of North Carolina Center for AIDS Research HIV Clinical Cohort receiving care during

64 the University of North Carolina Center for AIDS Research HIV Clinical Cohort receiving clinical car

65 search), Johns Hopkins University Center for AIDS Research, and National Cancer Institute.

66 ion, the Johns Hopkins University Center for AIDS Research, and the President's Emergency Plan for AI

67 and the Johns Hopkins University Center for AIDS Research.

68 sity of Washington and Fred Hutch Center for AIDS Research; the Wellcome Trust; the University of Was

69 HCV and MI among patients in the Centers for AIDS Research (CFAR) Network of Integrated Clinical Syst

70 2010-2016 at seven sites in the Centers for AIDS Research Network of Integrated Clinical Systems (CN

71 from 2010-2016 at 7 sites in the Centers for AIDS Research Network of Integrated Clinical Systems (CN

72 amfAR (the Foundation for AIDS Research), Johns Hopkins University Center for AIDS

73 ome Trust and amfAR (American Foundation for AIDS Research).

74 sus macaque is an important animal model for AIDS and other infectious diseases.

75 s (RhMs) is the best-characterized model for AIDS research.

76 European Network for AIDS Treatment 022 Study (NEAT022) is a European, open-l

77 ponent of the President's Emergency Plan for AIDS Relief (PEPFAR) combination HIV prevention program

78 arch, and the President's Emergency Plan for AIDS Relief through the Centers for Disease Control and

79 US President's Emergency Plan for AIDS Relief through the US Centers for Disease Control a

80 es of Health, President's Emergency Plan for AIDS Relief, Bill & Melinda Gates Foundation, and Gilead

81 es of Health, President's Emergency Plan for AIDS Relief, National Institute for Health Research.

82 US Presidents' Emergency Plan for AIDS Relief.

83 pment, and US President's Emergency Plan for AIDS Relief.

84 alth, and the President's Emergency Plan for AIDS Relief.

85 US President's Emergency Plan for AIDS Relief.

86 Optimal treatment regimens for AIDS-associated Kaposi sarcoma, a frequent contributor t

87 e previous International Antiviral (formerly AIDS) Society-USA recommendations in 2018, including dat

88 ted by the International Antiviral (formerly AIDS) Society-USA reviewed relevant peer-reviewed data t

89 assessed pre/post-INSTI weight changes from AIDS Clinical Trials Group participants (A5001 and A5322

90 spensable component in combatting the global AIDS epidemic.

91 be required for a durable end to the global AIDS pandemic.

92 atients had human immunodefiency virus (HIV)/AIDS, cancer, stem cell or organ transplantation, nonste

93 ving with human immunodeficiency virus (HIV)/AIDS.

94 HIV/AIDS and TB continue to be a significant global burden,

95 HIV/AIDS is a leading cause of disease burden in sub-Saharan

96 HIV/AIDS is responsible for the deaths of one million people

97 HIV/AIDS received $42.1 billion (40.1%), tuberculosis receiv

98 gs is critical to achieving the 90-90-90 HIV/AIDS targets.

99 causes of death in persons with advanced HIV/AIDS.

100 alth scale-up efforts (the fight against HIV/AIDS and the improvement of maternal and child health) a

101 curative and preventive measures against HIV/AIDS.

102 mmon route for spreading the virus among HIV/AIDS patients.

103 even though the index participant was an HIV/AIDS activist, particularly well informed about the risk

104 ominis, a Microsporidia isolated from an HIV/AIDS patient, as our experimental model, we show that th

105 e implementation science framework of an HIV/AIDS program in the United States.

106 e from Financing Global Health 2018, and HIV/AIDS prevalence, incidence, and mortality were from the

107 , influenza and pneumonia, diabetes, and HIV/AIDS.

108 ey injury, urinary tract infections, and HIV/AIDS.

109 or the development of this class of anti-HIV/AIDS therapeutics.

110 hinese herbal medicine (CHM) for Chinese HIV/AIDS patients.

111 ss towards gender equality and combating HIV/AIDS.

112 isation or as an alternative for current HIV/AIDS antiretroviral therapy regimens.

113 disability-adjusted life years (DALYs), HIV/AIDS received the greatest relative investment ($772 per

114 012 and 2016, development assistance for HIV/AIDS decreased by 20.0%; domestic financing is therefore

115 natural product under investigation for HIV/AIDS eradication, the treatment of neurological disorder

116 g Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) data, we projected the clinical

117 lenges of using integrase inhibitors for HIV/AIDS management.

118 Development assistance data for HIV/AIDS were from Financing Global Health 2018, and HIV/AID

119 limiting effective antiviral therapy for HIV/AIDS.

120 and the funding needed to achieve global HIV/AIDS goals, and sustained and coordinated effort across

121 populations, African countries with high HIV/AIDS prevalence, and small island nations with high diab

122 region of Brazil has one of the highest HIV/AIDS prevalence in Latin America and Ceara State has one

123 ring the influence of viral genotypes in HIV/AIDS epidemiology, replication, and eradication strategi

124 coma (KS), the most common malignancy in HIV/AIDS patients.

125 While the substantial investments in HIV/AIDS research are validated solely on these advances, th

126 apies, have resulted from investments in HIV/AIDS research.

127 mmunosuppression and wasting syndrome in HIV/AIDS.

128 those with underlying diseases including HIV/AIDS and cystic fibrosis.

129 immunocompromised individuals, including HIV/AIDS patients.

130 lar in scale to that of the decades-long HIV/AIDS and opioid-overdose epidemics but considerably smal

131 se findings highlight the need to modify HIV/AIDS treatment guidelines to incorporate cardiovascular

132 The United States National HIV/AIDS Strategy established goals to reduce disparities in

133 nosis, to be included in the US National HIV/AIDS Strategy to monitor the progress in human immunodef

134 The continuing spread of HIV/AIDS is predominantly fueled by sexual exposure to HIV-c

135 ease inhibitor drug for the treatment of HIV/AIDS patients.

136 ed and substantial positive spin-offs of HIV/AIDS research on other scientific areas.

137 c progress resulting from the support of HIV/AIDS research over the past 30 years is extraordinary as

138 CD4 T-cell depletion is a hallmark of HIV/AIDS, but the underlying mechanism is still unclear.

139 onhuman primate intestinal loop model of HIV/AIDS, we identified the pathogenic mechanism underlying

140 lth communities well beyond the field of HIV/AIDS.

141 ventually towards the functional cure of HIV/AIDS.

142 n FDA-approved drug for the treatment of HIV/AIDS.

143 ng the Joint United Nations Programme on HIV/AIDS (UNAIDS) "three 90s" targets.

144 rd the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 target, we compared 2016 to 2013

145 4, the Joint United Nations Programme on HIV/AIDS (UNAIDS) set the 90-90-90 targets: that 90% of peop

146 proposed by United Nations Programme on HIV/AIDS (UNAIDS) to have achieved virological suppression i

147 third Joint United Nations Programme on HIV/AIDS 90-90-90 targets (ie, 90% of diagnosed people on su

148 ssistance, we aimed to track spending on HIV/AIDS and estimated the potential for governments to devo

149 $3.0 billion (1.5-5.8), and spending on HIV/AIDS care and treatment increased from $1.1 billion (458

150 Between 2000 and 2016, total spending on HIV/AIDS in LMICs increased from $4.0 billion (95% uncertain

151 o $19.9 billion (15.8-26.3), spending on HIV/AIDS prevention increased from $596 million (258 million

152 s disease, with a particular emphasis on HIV/AIDS, malaria and tuberculosis.

153 ential additional government spending on HIV/AIDS, which was conditional on the current government he

154 ed 8589 datapoints reporting spending on HIV/AIDS.

155 YPHIVs aged >=18 years in the Pediatric HIV/AIDS Cohort Study (PHACS) AMP Up cohort approaching or h

156 e cohort study was done by the Pediatric HIV/AIDS Cohort Study network.

157 perinatal HIV infection in the Pediatric HIV/AIDS Cohort Study-AMP Up protocol, a prospective study o

158 nters for Disease Control and Prevention HIV/AIDS Prevention Research Synthesis Project database to i

159 uld be an effective therapy for reducing HIV/AIDS morbidity and mortality, and thus warrants further

160 IDS Research and University of Rochester HIV/AIDS Clinical Trials Unit.

161 rus/acquired immune deficiency syndrome (HIV/AIDS).

162 been made towards the goal of ending the HIV/AIDS epidemic due to advancements in both prevention and

163 f HPgV biovaccination for mitigating the HIV/AIDS health burden using mathematical models.

164 uss unstable housing and the response to HIV/AIDS in the United States.

165 nese MSM may not report such risk due to HIV/AIDS-related stigmatization and discrimination.

166 ents of LMICs to finance the response to HIV/AIDS.

167 s to devote additional domestic funds to HIV/AIDS.

168 e critical to sustaining the response to HIV/AIDS.

169 Unlike HIV/AIDS and opioid epidemics, the COVID-19 deaths are conce

170 vices Administration (HRSA)'s Ryan White HIV/AIDS Program (RWHAP) is well positioned to integrate tre

171 n project sites funded by the Ryan White HIV/AIDS Program (RWHAP), which tend to have better HIV outc

172 vices Administration's (HRSA) Ryan White HIV/AIDS Program (RWHAP)-supported HIV care, compared with c

173 We also obtained Ryan White HIV/AIDS Program Services Reports (RSRs) from sites for cale

174 ervices Administration (HRSA) Ryan White HIV/AIDS Program Special Projects of National Significance (

175 to continued reliance on the Ryan White HIV/AIDS Program.

176 People living with HIV/AIDS (PLWHA) have a growing life expectancy in the US du

177 , and contextual factors associated with HIV/AIDS spending.

178 nt women are estimated to be living with HIV/AIDS, the majority of whom live in sub-Saharan Africa.

179 athogen particularly in individuals with HIV/AIDS.

180 -infected population of Western New York HIV/AIDS, Referral Center at Erie County Medical Center (ECM

181 lar heart disease, diabetes, hypothyroidism, AIDS, lymphoma, solid tumor without metastasis, rheumato

182 tent to block active replication of HIV-1 in AIDS patients, HIV-1 persists as transcriptionally inact

183 oung children and causes chronic diarrhea in AIDS patients, but the only approved treatment is ineffe

184 s, is an important opportunistic pathogen in AIDS patients and one of the most common enteric pathoge

185 oles of interferon (IFN)-induced proteins in AIDS pathogenesis.IMPORTANCE The role of IFN-induced gen

186 Despite the reduction in AIDS-related deaths achieved by current antiretroviral t

187 to receive efavirenz-containing regimens in AIDS Clinical Trials Group studies A5095, A5142 and A520

188 eptibility testing in predicting response in AIDS-associated cryptococcal meningitis using clinical i

189 Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, c

190 the world's most deadly diseases, including AIDS and malaria.

191 elial-cell and B-cell pathologies, including AIDS-associated Kaposi's sarcoma and multicentric Castle

192 human immunodeficiency virus (HIV)-infected AIDS patients has been ascribed to an interaction betwee

193 blood, estimated duration of HIV infection, AIDS diagnosis, duration of ART, adherence to ART, ART c

194 International AIDS Vaccine Initiative, United States Agency for Intern

195 National Institutes of Health, International AIDS Society.

196 UKAID, Janssen Pharmaceutica, International AIDS Society, John Fell Fund, European Research Council,

197 iated immunity in vivo In the rhesus macaque AIDS virus model, infusing simian immunodeficiency virus

198 ination antiretroviral therapy has mitigated AIDS-related symptoms, the prevalence of neurological im

199 Mortality, AIDS events, quality of life, function, and HIV transmis

200 89 HIV+ and 534 HIV-) from MACS (Multicenter AIDS Cohort Study), using the ZioXT ambulatory electroca

201 V-1-positive participants in the Multicenter AIDS Cohort Study.

202 's Interagency HIV Study and the Multicenter AIDS Cohort Study.

203 PBMC were obtained from the UCLA Multicenter AIDS Cohort Study (MACS).

204 personalized nanomedicine to manage neuroHIV/AIDS.

205 ntribute to the genesis of AIDS-related NHL (AIDS-NHL).

206 The incidence of clinical events (AIDS, non-AIDS cancer, cardiovascular disease, end-stage liver and

207 ath (7.5/1000 PYFU [95% CI 6.5-8.6]) and non-AIDS cancer (5.8/1000 PYFU [4.9-6.8]).

208 fining cancer incidence has declined and non-AIDS-defining cancers (NADCs) are now more frequent amon

209 ion is associated with AIDS-defining and non-AIDS-defining conditions.

210 related and traditional risk factors for non-AIDS-defining cancers, myocardial infarction, end-stage

211 ly predicts mortality and morbidity from non-AIDS events.

212 However, the incidence of non-AIDS associated lung comorbidities, such as COPD and ast

213 , to reduce inflammation and the risk of non-AIDS comorbidities and possibly other infectious disease

214 sistent inflammation, and development of non-AIDS comorbidities.

215 monocyte activation, with occurrence of non-AIDS events.

216 ) were associated with increased risk of non-AIDS events.

217 The substantial proportion of non-AIDS-defining cancers, myocardial infarction, end-stage

218 lts with HIV have an increased burden of non-AIDS-defining cancers, myocardial infarction, end-stage

219 ng with HIV live longer, a wide range of non-AIDS-related cancer has emerged, including other haemato

220 disease is one of the leading causes of non-AIDS-related mortality in HIV-positive patients, enhanci

221 explore its role in the pathogenesis of non-AIDS-related outcomes in HIV infection.

222 (HBP), diabetes mellitus, osteoporosis, non-AIDS cancer, chronic renal failure, cardio and cerebrova

223 essure, diabetes mellitus, osteoporosis, non-AIDS cancer, chronic renal failure, cardiovascular and c

224 te therapeutic interventions and predict non-AIDS comorbidity risks in PWH.

225 involved in atherogenesis that predicts non-AIDS events during ART, declined markedly with sitaglipt

226 Endpoints assessed were AIDS, serious non-AIDS (SNA), cardiovascular disease (CVD), cancer, and de

227 gression, immune system and subsequently non-AIDS complications, and efficacy of vaccinations against

228 esearch and Design and who had validated non-AIDS-defining cancers, myocardial infarction, end-stage

229 3.IMPORTANCE HIV-1 is the causative agent of AIDS.

230 ingle report of an HIV provirus in a case of AIDS-associated B-cell lymphoma with an HIV provirus in

231 tudinal Study of the Ocular Complications of AIDS (LSOCA) and 2:1 controls matched for age and sex, c

232 le of PD-L1(+) B cells in the development of AIDS-NHL has not been explored.

233 , and more than 700 000 persons have died of AIDS since the first cases were reported in 1981.

234 ese cells may play a role in the etiology of AIDS-NHL.

235 are believed to contribute to the genesis of AIDS-related NHL (AIDS-NHL).

236 e, which was then correlated with history of AIDS-related central nervous system (CNS) disorders (ARC

237 re which was then correlated with history of AIDS-related CNS disorders (ARCD; e.g. prior CNS opportu

238 320 (86%) of 371 reported a history of AIDS.

239 Nigeria has the highest number of AIDS-related deaths in the world.

240 Bill and Melinda Gates Foundation; Office of AIDS Research; American Cancer Society; National Cancer

241 n, CD4(+) T cell depletion, and the onset of AIDS were comparable between anti-IL-15- and control-tre

242 ard ratios (HR) for the composite outcome of AIDS, acute myocardial infarction, stroke, end-stage ren

243 R5 interaction, which influences the rate of AIDS progression.

244 etween underweight and the mortality rate of AIDS.

245 While the overall rate of AIDS/death was low, children with PIR had a 4-fold incre

246 Rates of AIDS/death (95% confidence interval) per 100 000 person-

247 and causes a syndrome that is reminiscent of AIDS in humans.

248 consequence, relative differences in risk of AIDS and SNA between immediate/continuous ART and deferr

249 substantial benefit in reducing the risk of AIDS-related events or death.

250 Paediatric European Network for Treatment of AIDS Foundation, ViiV Healthcare, UK Medical Research Co

251 therapy has revolutionized the treatment of AIDS, turning a deadly disease into a manageable chronic

252 ANRS (French National Agency for Research on AIDS).

253 en, and patients with sickle cell disease or AIDS.

254 People living with HIV or AIDS are at increased risk of Hodgkin and non-Hodgkin ly

255 iremia is associated with mortality in other AIDS-related opportunistic infections.

256 rs in a subset of Elizabeth Glaser Pediatric AIDS Foundation (EGPAF)-supported sites that would be en

257 uman Development, Elizabeth Glaser Pediatric AIDS Foundation, South African Medical Research Council,

258 Elizabeth Glaser Pediatric AIDS Foundation, US National Institute of Allergy and In

259 at ART initiation, which were predominantly AIDS-defining eligibility criteria for initiating ART.

260 inhibiting HIV-1 replication and preventing AIDS, it cannot eradicate the infection.

261 We used the Cost Effectiveness of Preventing AIDS Complications (CEPAC)-Pediatric model to examine th

262 We used the Cost-effectiveness of Preventing AIDS Complications model to examine the clinical impact

263 e-based Screening for Tuberculosis to reduce AIDS Related Mortality in hospitalized Patients in Afric

264 e-based screening for tuberculosis to reduce AIDS-related mortality in hospitalised patients in Afric

265 e-based Screening for Tuberculosis to Reduce AIDS-related Mortality in Hospitalised Patients in Afric

266 ple with HIV infection on cART in a referral AIDS center in Salvador, Brazil.

267 The Spectrum AIDS Impact Module developed by Avenir Health, UNAIDS, a

268 enrolled people with HIV and advanced stage AIDS-associated Kaposi sarcoma attending 11 AIDS Clinica

269 performance.FUNDINGThis observational study, AIDS Clinical Trials Group (ACTG) HIV Reservoirs Cohort

270 Rates of acquired immunodeficiency syndrome (AIDS) or death on suppressive ART were calculated by PIR

271 the main acquired immunodeficiency syndrome (AIDS)-defining conditions in endemic areas.

272 aive and acquired immunodeficiency syndrome (AIDS)-free prior to their first visit after 1 October 19

273 us (HIV)/acquired immunodeficiency syndrome (AIDS).

274 The AIDS Malignancy Consortium 084 study was a multicenter n

275 mic in the 1930s-1950s, and again during the AIDS epidemic in the1980s-1990s.

276 However, the AIDS crisis in the 1980s revealed the prevalence of chro

277 term ART.METHODSParticipants enrolled in the AIDS Clinical Trials Group (ACTG) HIV Reservoirs Cohort

278 During the peak of the AIDS epidemic, many hospitals and outpatient clinics wer

279 Successful replication of the AIDS retrovirus, HIV, requires that its genomic RNA be p

280 ng community-based cohort study of PWID, the AIDS Link to Intravenous Experience (ALIVE) Study, analy

281 National Institutes of Health, through the AIDS Clinical Trials Group and the International Materna

282 The third AIDS-related mycoses workshop updated progress in the fi

283 is shown to delay the progression of HIV to AIDS.

284 However, the mechanisms that lead to AIDS-NHL have not been completely defined.

285 icantly elevated in cases 1-4 years prior to AIDS-NHL diagnosis, compared to controls, raising the po

286 r expected life span, without progressing to AIDS or transmitting HIV to sexual partners or infants.

287 ciated with HIV-1 control and progression to AIDS, accounting for up to 12% of the variation in HIV-1

288 from HIV infection and slower progression to AIDS.

289 8) is an oncogenic virus causally related to AIDS-associated malignancies.

290 tapasin independence progress more slowly to AIDS and maintain lower viral loads, presumably due to i

291 active antiretroviral therapy used to treat AIDS patients, likely results from off-target interactio

292 rveys, 21 Malaria Indicator Surveys, and two AIDS Indicator Surveys conducted in 33 countries between

293 Endpoints assessed were AIDS, serious non-AIDS (SNA), cardiovascular disease (CV

294 The major causes of deaths were AIDS- or tuberculosis-related conditions both within 42

295 Chronic inflammation is associated with AIDS-defining and non-AIDS-defining conditions.

296 ing opportunistic infections associated with AIDS.

297 opportunistic pathogens in individuals with AIDS and other immunocompromised individuals.

298 Patients with AIDS and hematological cancer admitted with CAP may have

299 ncreased mortality observed in patients with AIDS with AMD is, at least in part, a result of systemic

300 nodeficiency virus infection with or without AIDS, the viral hepatitides, infective endocarditis, and